PEDIATRIC ONCOLOGY GROUP

这项建议是要求支持参加联合国 儿科肿瘤组（POG）。 这项合作研究致力于 急性白血病化疗方法的研究， 其他儿童肿瘤性疾病。 显著缓解， 延长了生存期， 在临床药理学上。 然而，这些研究的真实的目的是 通过治疗根除肿瘤疾病。 研究正在 旨在反映对肿瘤的攻击强度不断增加 cell. 合作小组技术允许迅速评价系列 合理大小的有希望的化疗药物。 这些线索还是新的 方法往往是由小组自己的工作结果提出的， 临床肿瘤学 因此，一个完整的协议往往建议新的 在新协议中探索的途径。 此外，协议 旨在利用在以下方面取得的最大临床或概念进展 实验动物和/或临床初步研究。 司 儿科血液学-肿瘤学 加州大学圣地亚哥分校（UCSD）参与了10年的 在加入之前与癌症和白血病组B进行合作组研究 1980年加入儿科肿瘤学小组。 1983年1月1日至 至1984年12月31日止，共登记26组129例患者 方案研究。 此外，PI。协调了一项关于 VP-16 - 213，并完成了关于治疗的组方案研究草案 早期霍奇金病，和其他UCSD研究人员担任 生殖细胞肿瘤、骨髓、 对于ALL患者，在第二次缓解或涉及移植 T细胞ALL中组方案研究的实验室调查或 神经母细胞瘤 我们计划继续积极参与所有阶段的工作 的POG活动。

This proposal represents a request to support participation in the Pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic approaches to acute leukemia and other neoplastic diseases of childhood. Significant palliation and prolongation of survival has been achieved and contributions have been made in clinical pharmacology. However, the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests the new avenues to be explored in new protocols. In addition, protocols are designed to exploit maximal clinical or conceptual advances made in experimental animals and/or clinical pilot studies. The Division of Pediatric Hematology-Oncology in the Department of Pediatrics at the University of California, San Diego (UCSD) has a 10 year involvement in cooperative group studies with Cancer and Leukemia Group B prior to joining forces with the Pediatric Oncology Group in 1980. Between January 1, 1983 and December 31, 1984, we have had 129 patient registrations on 26 group protocol studies. In addition, the P.I. coordinated a Phase II study o n VP-16-213 and completed a draft on a Group Protocol study on the treatment of early stage Hodgkin's disease, and other UCSD investigators served as coordinators for Group Protocols on germ cell tumors, bone marrow transplantation for patients with ALL in second remission or involved in the laboratory investigation of Group Protocol studies in T-cell ALL or neuroblastoma. We plan to continue our active participation in all phases of POG activities.